ReviewAdvances in therapy2023
A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.
Review in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Trial
- Article
- Adverse outcomes in young adults with severe asthma: results from the UK Severe Asthma Registry.ERJ open research · 2026Article
- Biologic Underutilization and Healthcare Burden in US Patients with Type 2 Severe Asthma.Journal of asthma and allergy · 2026Article
- Validation and cross-cultural insights of the French translation of the Severe Asthma Questionnaire.ERJ open research · 2025Article
- Review
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Predicting Risk of Morbidities Associated with Oral Corticosteroid Prescription for Asthma.Pragmatic and observational research · 2025Article
- Perceptions of oral corticosteroid use for children with asthma in a survey of US caregivers.Frontiers in pediatrics · 2025Article
- Use of oral corticosteroids in patients with asthma: how far is clinical practice from the guidelines? Results from surveys of patients and doctors.Frontiers in allergy · 2025Article
- The relationship between prescription rates of oral corticosteroids for respiratory diseases and deprivation in England.NPJ primary care respiratory medicine · 2024Article
- Degree of Adherence to Recommendations From the Spanish Consensus on the Reduction of Oral Corticosteroid Use in Asthma Patients: A Questionnaire-based Observational Study.Open respiratory archivesArticle
- Challenges in the Implementation of the Spanish Consensus on the Reduction of Oral Corticosteroids: Insights From the Medical Community.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma affects 339 million people worldwide, with an estimated 5-10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produce clinically important adverse outcomes and increase the risk of mortality. Therefore, global guidelines recommend limiting the use of OCS. Despite the risks, research indicates that 40-60% of people with severe asthma are receiving or have received long-term OCS treatment. Although often perceived as a low-cost option, long-term OCS use can result in significant health impairments and costs owing to adverse outcomes and increased utilization of healthcare resources. Alternative treatment methods, such as biologics, may produce cost-saving benefits with a better safety profile. A comprehensive and concerted effort is necessary to tackle the continued reliance on OCS. Accordingly, a threshold for OCS use should be established to help identify patients at risk of OCS-related adverse outcomes. Receiving a total dose of more than 500 mg per year should trigger a review and specialist referral. Changes to national and local policies, following examples from other chronic diseases, will be crucial to achieving this goal. Globally, multiple barriers to change still exist, but specific steps have been identified to help clinicians reduce reliance on OCS. Implementing these changes will result in positive health outcomes for patients and social and economic benefits for societies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.